Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B. (Q40904392)

24 September 2017

Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B. (English)

1 reference

24 September 2017

Kung-Hao Liang

1

1 reference

24 September 2017

Chao-Wei Hsu

2

1 reference

24 September 2017

Ming-Ling Chang

3

1 reference

24 September 2017

Yi-Cheng Chen

4

1 reference

24 September 2017

Ming-Wei Lai

5

1 reference

24 September 2017

Chau-Ting Yeh

6

1 reference

24 September 2017

language of work or name

English

0 references

publication date

17 November 2015

1 reference

Journal of Infectious Diseases

24 September 2017

1 reference

24 September 2017

213

1 reference

24 September 2017

966-974

1 reference

24 September 2017

6

1 reference

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

24 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV547

Hepatitis B: liver fibrosis and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV547

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV547

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV547

Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV547

Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV547

Prevention of hepatocellular carcinoma in hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV547

Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV547

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV547

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV547

Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV547

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV547

Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV547

Chronic hepatitis B: update 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV547

Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV547

Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV547

Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV547

Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV547

Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV547

Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV547

Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV547

Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV547

Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV547

Histological grading and staging of chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV547

Management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV547

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV547

Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV547

Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV547

Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV547

Hepatitis B virus precore mutants in serum and liver of Southern African Blacks with hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV547

Transection of the oesophagus for bleeding oesophageal varices

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV547

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV547

Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV547

Dysregulation of the TGFBI gene is involved in the oncogenic activity of the nonsense mutation of hepatitis B virus surface gene sW182*.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV547

The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIV547

21 January 2018

Identifiers

DOI

10.1093/INFDIS/JIV547

1 reference

24 September 2017

1 reference